LifeArc licenses lead stage molecules to Daiichi Sankyo
The deal to license an ion channel drug discovery programme marks the successful outcome of a collaboration between LifeArc, Oxford University’s NDCN and Daiichi Sankyo.
27 March 2019
Cancer Research UK, Lifearc and Ono Pharma Form Cancer Immunotherapy Alliance
12 December 2018
LifeArc study points towards expanded utility for antibody-drug candidates
27 November 2018
LifeArc and C4X Discovery join forces to develop small molecule drug candidates